Abstract. D-dimer is a widely used biomarker for indicating the activation of coagulation and fibrinolysis, and is reported to serve important roles in cancer progression. The aim of the current retrospective study was to investigate the association of D-dimer plasma level with the development of various cancers. Patients with breast (n=86), gastric (n=317), pancreatic (n=37), colon (n=153) and rectal (n=137) cancers and 92 healthy volunteers were assessed in the present study. Plasma levels of D-dimer in the patients and healthy controls were measured by immunoturbidimetric assays. The association of D-dimer levels with the clinicopathological features of patients were also determined. The plasma levels of D-dimer were significantly higher in patients with breast cancer (P=0.0022), gastric cancer (P<0.0001), pancreatic cancer (P=0.0003), colon cancer (P=0.0001) and rectal cancer (P=0.0028), compared with the healthy controls. It was also determined that the plasma D-dimer levels were positively associated with clinical cancer stage (P<0.05) and metastasis (P<0.05). These findings suggested that the plasma D-dimer level may be used as marker for predicting cancer metastasis and progression.
Introduction
D-dimer is the cleavage product of cross-linked fibrin that is formed by activation of the coagulation system, which signals hyperfibrinolysis in response to clot activation and fibrin formation (1) . Elevated levels of D-dimer have been detected in patients exhibiting diffuse intravascular coagulation (2) , vascular occlusion crisis in sickle cell disease (3), thromboembolic events (4, 5) and myocardial infarction (6) . D-dimer is a widely used biomarker for indicating the activation of coagulation and fibrinolysis (7, 8) . Coagulation disorders are among the most common complications in cancer patients (7, 9) . D-dimer levels are elevated in the plasma of patients with various solid cancers, including of the prostate (10) (11) (12) , cervix (13) (14) (15) and esophageal squamous cells (16) . However, the association of D-dimer levels and cancer progression remains to be a focus of study.
In the present retrospective study, the plasma levels of D-dimer in patients with breast, gastric, pancreatic, colon and rectal cancers and in healthy controls were firstly measured. Subsequently, associations between the D-dimer levels and clinical features were assessed. The results suggested that the plasma level of D-dimer was notably associated with the extent of tumor metastasis and tumor stage in cancer patients. D-dimer level assays. D-dimer expression levels were detected prior to and following treatment in cancer patients. In the healthy controls D-dimer was detected during a fasting (for 8 h prior) physical examination. A total of 3 ml whole blood was drawn from the antecubital vein of each subject and collected in 3.8% sodium citrate vacutainer collection tubes (Greiner Bio-One GmbH, Frickenhausen, Germany). Plasma D-dimer levels were analyzed with an INNOVANCE ® D-Dimer Calibrator (Siemens AG, Munich, Germany). All samples were run in duplicate according to manufacturer's recommendations. The D-dimer cross-linkage region has a stereosymmetrical structure, meaning the epitope for the monoclonal antibody occurs twice. D-dimer levels >0.55 mg/l were considered to be elevated, since this was the upper limit of the 90% confidence interval for the average value determined in the healthy volunteers. The D-dimer levels in tumor patients can be affected following surgery (25, 26) , chemotherapy (27, 28) and adjuvant therapy (29) . Therefore, the data analyzed herein is the D-dimer expression level of all patients prior to treatment.
Materials and methods

Study
Statistical analysis. D-dimer levels were presented as the median and range. Statistically significant differences between healthy volunteers and cancer patients were determined using unpaired Student's t-tests. Cases were divided into two groups, high or low, according to the median D-dimer level as a cutoff. Associations of D-dimer level with clinicopathological characteristics were analyzed by using the χ 2 test. P<0.05 was considered to indicate statistical significance. The statistical analysis and graphing of data were performed with GraphPad Prism version 7.00 (GraphPad Software, Inc., La Jolla, CA, USA). (Table I) ; metastasis (P<0.0001) and TNM stage (P=0.0063) in patients with gastric cancer (Table II) ; TNM stage (P=0.0395) in patients with pancreatic cancer (Table III) ; metastasis (P=0.0120), TNM stage (P=0.0039) and sex (P=0.0145) in patients with colon cancer (Table IV) ; and metastasis (P=0.0104) and TNM stage (P=0.0002) in patients with rectal cancer (Table V) . No differences were identified between D-dimer level and other clinical features (Tables I-V) . These data suggested that the plasma level of D-dimer may be used as a marker in cancer progression. Table I . Clinical association between D-dimer level and clinicopathological variables of breast cancer patients. For patients with breast cancer, since there were no male patients it was not possible to perform statistics for male vs. female patients. TNM, tumor-node-metastasis.
Results
D-dimer levels are significantly increased in patients with
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Discussion
In the present study, it was demonstrated that elevated plasma levels of D-dimer were associated with clinical cancer stages and metastasis in patients with breast, gastric, colon and rectal cancers. It was also identified that D-dimer plasma level was associated with cancer stages in patients with pancreatic cancer and with gender in patients with colon cancer. These findings suggest that D-dimer level has a potential use in predicting the likelihood of metastasis and progression in various cancers. Distant metastasis is the main cause of poor prognosis and leads to inefficacy in treatments in cancer patients (30) . D-dimer is a widely used biomarker for indicating the activation of coagulation and fibrinolysis. It is established that activated Table II . Clinical association between D-dimer level and clinicopathological variables of gastric cancer patients. Cases with low and high D-dimer level, n (%) Cases with low and high D-dimer level, n (%) Cases with low and high D-dimer level, n (%) coagulation, which is common in malignancy, plays an important role in cancer metastasis (31) . The coagulation/fibrinolytic system is activated in cancer patients and may contribute to cancer progression (14) . Thus, tumor-related degradation products of the coagulation and fibrinolytic system have been proposed to predict tumor load and prognosis (14, 32) . Plasma D-dimer is a pro-coagulation factor that may reflect the presence of micro-metastases or circulating tumor cells, which may be responsible for tumor recurrence (30, 33, 34) . Recent studies have reported a positive association between circulating tumor cells and plasma D-dimer levels in patients with metastatic breast cancer (35, 36) . Diao et al (37) observed that plasma D-dimer levels were markedly increased in gastric cancer patients with distant metastases, particularly in patients with visceral metastases. In fact, they suggested D-dimer to be a promising predictor of clinical stage in the gastric cancer patients (37). Lee et al (38) reported that increased plasma D-dimer and fibrinogen degradation product levels were significantly associated with TNM stage in colorectal cancer patients. Furthermore, preoperative plasma D-dimer levels have been associated with larger tumor size and lymph node metastasis in colorectal cancer patients (39) .
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Other recent studies have shown that plasma D-dimer values may predict overall survival and progression free survival in patients with pancreatic cancer (40, 41) . In accordance with the above studies, the present study confirmed a positive association between D-dimer level and tumorigenesis. It was further identified that D-dimer level was associated with cancer stages but not with metastasis in patients with pancreatic cancer. Among the patients with pancreatic cancer, the majority presented with metastasis (34/37), and fibrinogen and carbohydrate antigen 19-9 (CA19-9) were significantly elevated in the patients with metastatic pancreatic cancer, compared with patients with non-metastatic cancer (data not shown), suggesting that a combination of D-dimer, fibrinogen and CA19-9 may be used for predicting metastasis of pancreatic cancer.
In conclusion, the present retrospective study demonstrated that D-dimer plasma level was significantly higher in patients with cancer and associated with clinical stages and metastasis. The current study was limited in that it only identified the association of D-dimer with tumor stage and metastasis. We will further investigate the sensitivity and specificity of D-dimer as an indicator of tumorigenesis, and the correlation between D-dimer and the survival and prognosis of cancer patients, to clarify whether D-dimer level may be considered as an important factor in the prognosis of cancer patients.
